CD8A and cancer: Related to mutant KRAS targeting, a phase II clinical trial designed to test whether the ACT of ex vivo expanded tumor-infiltrating lymphocytes targeting personalized cancer neoepitopes can mediate regression of metastatic solid cancers, identified CD8+ T cells reactive to KRASG12D (NCT01174121).